SK Biopharmaceuticals Teams Up with Full-Life Technologies to Develop FL-091 for Multiple Solid Tumors
Shots:
- SK Biopharmaceuticals has signed a license agreement with Full-Life Technologies to secure exclusive global rights of FL-091 for treating NTSR1+ve solid tumors
- As per the agreement, SK Biopharmaceuticals gains global exclusive rights to research, develop, manufacture & commercialize FL-091 (radionucleotide drug conjugate), along with its back-up compounds plus right to first negotiate Full-Life’s other pre-selected RDC programs
- Full-Life will receive an aggregate of $571.5M upfront, development & commercial milestones plus additional royalties
Ref: PRNewswire | Image: SK Biopharmaceuticals & Full-Life Technologies
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
